Literature DB >> 26037599

Impact of incomplete revascularization of coronary artery disease on long-term cardiac outcomes. Retrospective comparison of angiographic and myocardial perfusion imaging criteria for completeness.

Jiehui Li1, Thomas H Schindler2, Shubin Qiao3, Hongxing Wei4, Yueqin Tian4, Weixue Wang4, Xiaoli Zhang5, Xiubin Yang6, Xiujie Liu4.   

Abstract

BACKGROUND: Coronary revascularization in patients with coronary artery disease may be guided by coronary angiography (CA) or alternatively by ischemia on stress myocardial perfusion imaging (MPI). Which strategy leads to optimal cardiac outcomes is uncertain.
METHODS: We performed a retrospective analysis of 170 patients with MPI ischemia and percutaneous coronary intervention. The primary endpoint was all-cause mortality at a mean follow-up of 47 ± 21 months; the secondary end point was the composite of deaths, nonfatal myocardial infarction, and repeat coronary revascularization (MACE). The coronary revascularization was defined as complete (CCR) or incomplete (ICR) as judged by CA criteria and by MPI ischemia matched with CA criteria.
RESULTS: Nighty-two patients (54%) had ICR by CA criteria (ICR-CA) and 84 (49%) had ICR by MPI criteria (ICR-MPI). Mortality and MACE were lower in patients with CCR-MPI than with ICR-MPI (P = .048, and P = .025). Survival of patients with CCR-CA and ICR-CA was not different (P = .081). Patients with both ICR-MPI and ICR-CA had the worst survival, whereas patients with CCR-MPI and CCR-CA had the best survival (P = .047). By multivariate analysis, ICR-MPI + ICR-CA was an independent predictor of death (P = .025).
CONCLUSION: Patients with ICR by MPI were at higher risk than those with CCR. Patients with both ICR by MPI and CA were at the highest risk, while patients with CCR by both MPI and CA had the best long-term event-free survival.

Entities:  

Keywords:  Coronary artery disease; coronary angiography; incomplete revascularization; myocardial perfusion imaging; percutaneous coronary intervention

Mesh:

Year:  2015        PMID: 26037599     DOI: 10.1007/s12350-015-0109-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  19 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies.

Authors:  Santiago Garcia; Yader Sandoval; Henri Roukoz; Selcuk Adabag; Mariana Canoniero; Demetris Yannopoulos; Emmanouil S Brilakis
Journal:  J Am Coll Cardiol       Date:  2013-06-07       Impact factor: 24.094

3.  Psychosocial modulators of angina response to myocardial ischemia.

Authors:  Suzanne V Arnold; John A Spertus; Paul S Ciechanowski; Laurie A Soine; Kier Jordan-Keith; James H Caldwell; Mark D Sullivan
Journal:  Circulation       Date:  2009-06-29       Impact factor: 29.690

4.  When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies.

Authors:  M J Zellweger; H C Lewin; S Lai; E A Dubois; J D Friedman; G Germano; X Kang; T Sharir; D S Berman
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

5.  The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial.

Authors:  Vasim Farooq; Patrick W Serruys; Hector M Garcia-Garcia; Yaojun Zhang; Christos V Bourantas; David R Holmes; Michael Mack; Ted Feldman; Marie-Claude Morice; Elisabeth Ståhle; Stefan James; Antonio Colombo; Roberto Diletti; Michail I Papafaklis; Ton de Vries; Marie-Angèle Morel; Gerrit Anne van Es; Friedrich W Mohr; Keith D Dawkins; Arie-Pieter Kappetein; Georgios Sianos; Eric Boersma
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

6.  2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Stephan D Fihn; James C Blankenship; Karen P Alexander; John A Bittl; John G Byrne; Barbara J Fletcher; Gregg C Fonarow; Richard A Lange; Glenn N Levine; Thomas M Maddox; Srihari S Naidu; E Magnus Ohman; Peter K Smith
Journal:  Circulation       Date:  2014-07-28       Impact factor: 29.690

7.  Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia.

Authors:  G B John Mancini; Pamela M Hartigan; Leslee J Shaw; Daniel S Berman; Sean W Hayes; Eric R Bates; David J Maron; Koon Teo; Steven P Sedlis; Bernard R Chaitman; William S Weintraub; John A Spertus; William J Kostuk; Marcin Dada; David C Booth; William E Boden
Journal:  JACC Cardiovasc Interv       Date:  2014-01-15       Impact factor: 11.195

8.  Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation.

Authors:  Pim A L Tonino; William F Fearon; Bernard De Bruyne; Keith G Oldroyd; Massoud A Leesar; Peter N Ver Lee; Philip A Maccarthy; Marcel Van't Veer; Nico H J Pijls
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

9.  Impact of ischemia-guided revascularization with myocardial perfusion imaging for patients with multivessel coronary disease.

Authors:  Young-Hak Kim; Jung-Min Ahn; Duk-Woo Park; Hae Geun Song; Jong-Young Lee; Won-Jang Kim; Sung-Cheol Yun; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Dae Hyuk Moon; Cheol-Hyun Chung; Jae-Won Lee; Seong-Wook Park; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2012-07-17       Impact factor: 24.094

10.  Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes.

Authors:  Edward L Hannan; Chuntao Wu; Gary Walford; David R Holmes; Robert H Jones; Samin Sharma; Spencer B King
Journal:  JACC Cardiovasc Interv       Date:  2009-01       Impact factor: 11.195

View more
  4 in total

1.  Completeness of revascularization in multivessel coronary artery disease.

Authors:  Yader Sandoval; Emmanouil S Brilakis; Santiago Garcia
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Myocardial perfusion imaging prior to coronary revascularization: From risk stratification to procedure guidance.

Authors:  Patrick Proctor; Firas Al Solaiman; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2018-02-07       Impact factor: 5.952

3.  Impact of completeness of revascularisation on long-term outcomes in patients with multivessel disease undergoing PCI: CR versus IR outcomes in multivessel CAD.

Authors:  Pravin Goel; Ankit Sahu; Manas Layek; Roopali Khanna; Prabhakar Mishra
Journal:  AsiaIntervention       Date:  2021-07

4.  Complete revascularization determined by myocardial perfusion imaging could improve the outcomes of patients with stable coronary artery disease, compared with incomplete revascularization and no revascularization.

Authors:  Jiehui Li; Xiubin Yang; Yueqin Tian; Hongxing Wei; Marcus Hacker; Xiang Li; Xiaoli Zhang
Journal:  J Nucl Cardiol       Date:  2017-12-06       Impact factor: 5.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.